留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HIV阳性实体器官移植受者的免疫抑制药物管理

邵琨, 王祥慧, 周佩军. HIV阳性实体器官移植受者的免疫抑制药物管理[J]. 器官移植. doi: 10.3969/j.issn.1674-7445.2024009
引用本文: 邵琨, 王祥慧, 周佩军. HIV阳性实体器官移植受者的免疫抑制药物管理[J]. 器官移植. doi: 10.3969/j.issn.1674-7445.2024009
Shao Kun, Wang Xianghui, Zhou Peijun. Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2024009
Citation: Shao Kun, Wang Xianghui, Zhou Peijun. Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2024009

HIV阳性实体器官移植受者的免疫抑制药物管理

doi: 10.3969/j.issn.1674-7445.2024009
基金项目: 海南省卫生健康行业科研项目(22A200345)
详细信息
    通讯作者:

    邵琨(ORCID 0000-0001-5196-4529),Email:shaokunrj@163.com

  • 中图分类号: R617, R373

Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients

More Information
  • 摘要: 联合抗逆转录病毒治疗(cART)的应用显著提高了人类免疫缺陷病毒(HIV)感染者的预期寿命。但病毒感染和cART药物的不良反应使患者更容易发生器官衰竭。针对HIV感染者的终末期器官衰竭患者,实体器官移植(SOT)成为一种标准的治疗方案。然而,在HIV阳性SOT受者中,存在移植物排斥反应发生增多、感染风险升高、药物毒性以及cART治疗和免疫抑制药之间的药物相互作用等诸多问题,管理HIV阳性实体器官移植受者具有极大的挑战性。因此,本文就免疫诱导治疗、钙调磷酸酶抑制剂、哺乳动物雷帕霉素靶蛋白抑制剂及其他免疫抑制药在HIV阳性SOT受者中的应用进行综述,旨在为未来相关研究提供参考。

     

  • [1] The path that ends AIDS: UNAIDS Global AIDS Update 2023[EB/OL]. [2024-01-07].https://www.unaids.org/sites/default/files/media_asset/2023-unaids-global-aids-update_en.pdf.
    [2] 芦佳骏, 费发珠, 任宾. HIV感染者非酒精性脂肪性肝病的临床研究进展[J]. 临床肝胆病杂志, 2023, 39(6): 1446-1453. DOI: 10.3969/j.issn.1001-5256.2023.06.030.

    LU JJ, FEI FZ, REN B. Research advances in nonalcoholic fatty liver disease in individuals with HIV infection[J]. J Clin Hepatol, 2023, 39(6): 1446-1453. DOI: 10.3969/j.issn.1001-5256.2023.06.030.
    [3] 邵莉, 陈继军, 包凯, 等. 基于贝叶斯Cox风险比例回归的兰州市HIV感染者/AIDS患者死亡影响因素分析[J]. 中山大学学报(医学科学版), 2023, 44(2): 224-231. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0206.

    SHAO L, CHEN JJ, BAO K, et al. Influencing factors of HIV/ AIDS death based on Bayesian Cox proportional hazard regression model[J]. J Sun Yat-sen Univ (Med Sci), 2023, 44(2): 224-231. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0206.
    [4] POURNAMDARI AB, HSUE PY, PARIKH RV. HIV-associated cardiovascular disease: beyond the macrovascular[J]. J Am Heart Assoc, 2023, 12(22): e031876. DOI: 10.1161/JAHA.123.031876.
    [5] CERVANTES CE, ATTA MG. Updates on HIV and kidney disease[J]. Curr HIV/AIDS Rep, 2023, 20(2): 100-110. DOI: 10.1007/s11904-023-00645-1.
    [6] NAVARRO J. HIV and liver disease[J]. AIDS Rev, 2022, 25(2): 87-96. DOI: 10.24875/AIDSRev.M22000052.
    [7] STOCK PG, BARIN B, MURPHY B, et al. Outcomes of kidney transplantation in HIV-infected recipients[J]. N Engl J Med, 2010, 363(21): 2004-2014. DOI: 10.1056/NEJMoa1001197.
    [8] COFFIN CS, STOCK PG, DOVE LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients[J]. Am J Transplant, 2010, 10(5): 1268-1275. DOI: 10.1111/j.1600-6143.2010.03070.x.
    [9] KUMAR RN, STOSOR V. Advances in liver transplantation for persons with human immunodeficiency infection[J]. Curr Infect Dis Rep, 2022, 24(3): 39-50. DOI: 10.1007/s11908-022-00776-3.
    [10] 郑鑫, 胡小鹏, 薛文瑞, 等. HIV阳性患者接受亲属活体供肾移植一例及文献复习[J]. 中华器官移植杂志, 2019, 40(2): 88-91. DOI: 10.3760/cma.j.issn.0254-1785.2019.02.006.

    ZHENG X, HU XP, XUE WR, et al. HIV-positive patient receiving living related renal transplantation: a report of one case and literature review[J]. Chin J Organ Transplant, 2019, 40(2): 88-91. DOI: 10.3760/cma.j.issn.0254-1785.2019.02.006.
    [11] 冯文霞, 董常峰, 冯程, 等. 超声在HIV感染合并乙型病毒性肝炎肝硬化患者肝移植中的应用[J/CD]. 新发传染病电子杂志, 2021, 6(4): 294-297. DOI: 10.19871/j.cnki.xfcrbzz.2021.04.006.

    FENG WX, DONG CF, FENG C, et al. Ultrasound application in liver transplantation for HIV-infected patients with concomitant hepatitis B virus-related liver cirrhosis[J/CD]. Electr J Emerg Infect Dis, 2021, 6(4): 294-297. DOI: 10.19871/j.cnki.xfcrbzz.2021.04.006
    [12] 赖宇婷, 赵宁波, 董常峰, 等. 超声对HIV感染患者肾移植术后的诊治分析[J]. 罕少疾病杂志, 2023, 30(6): 38-40. DOI: 10.3969/j.issn.1009-3257.2023.06.017.

    LAI YT, ZHAO NB, DONG CF, et al. Analysis of diagnosis and treatment for HIV-infected patients after kidney transplantation with ultrasound[J]. J Rare Uncommon Dis, 2023, 30(6): 38-40. DOI: 10.3969/j.issn.1009-3257.2023.06.017.
    [13] Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). Organ procurement and transplantation: implementation of the HIV Organ Policy Equity act. final rule[J]. Fed Regist, 2015, 80(89): 26464-26467.
    [14] LAGOUTTE-RENOSI J, FLAMMANG M, DUCLOUX D, et al. Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants[J]. J Chemother, 2022, 34(3): 199-202. DOI: 10.1080/1120009X.2021.1940436.
    [15] ALMANGOUR TA, SKERSICK PT, CORBETT A, et al. Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report[J]. AIDS Res Ther, 2023, 20(1): 55. DOI: 10.1186/s12981-023-00551-x.
    [16] MCCAIN JD, CHASCSA DM. Special considerations in the management of HIV and viral hepatitis coinfections in liver transplantation[J]. Hepat Med, 2022, 14: 27-36. DOI: 10.2147/HMER.S282662.
    [17] CARTER JT, MELCHER ML, CARLSON LL, et al. Thymoglobulin-associated CD4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients[J]. Am J Transplant, 2006, 6(4): 753-760. DOI: 10.1111/j.1600-6143.2006.01238.x.
    [18] FERNÁNDEZ-RUIZ M, LÓPEZ-MEDRANO F, ALLENDE LM, et al. Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation[J]. Transpl Int, 2014, 27(7): 674-685. DOI: 10.1111/tri.12321.
    [19] ROLAND ME, BARIN B, HUPRIKAR S, et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls[J]. AIDS, 2016, 30(3): 435-444. DOI: 10.1097/QAD.0000000000000934.
    [20] KUCIRKA LM, DURAND CM, BAE S, et al. Induction Immunosuppression and clinical outcomes in kidney transplant recipients infected with human immunodeficiency virus[J]. Am J Transplant, 2016, 16(8): 2368-2376. DOI: 10.1111/ajt.13840.
    [21] LYNCH EN, RUSSO FP. Liver transplantation in people living with HIV: still an experimental procedure or standard of care?[J]. Life (Basel), 2023, 13(10): 1975. DOI: 10.3390/life13101975.
    [22] KOVAL CE, FARR M, KRISL J, et al. Heart or lung transplant outcomes in HIV-infected recipients[J]. J Heart Lung Transplant, 2019, 38(12): 1296-1305. DOI: 10.1016/j.healun.2019.09.011.
    [23] DOBERNE JW, JAWITZ OK, RAMAN V, et al. Heart transplantation survival outcomes of HIV positive and negative recipients[J]. Ann Thorac Surg, 2021, 111(5): 1465-1471. DOI: 10.1016/j.athoracsur.2020.06.120.
    [24] LAM C, LANDRY S, MOUSSA G, et al. Pharmacotherapeutic interventions in people living with HIV undergoing solid organ transplantation: a scoping review[J]. Transplant Direct, 2023, 9(2): e1441. DOI: 10.1097/TXD.0000000000001441.
    [25] BLUMBERG EA, ROGERS CC, American Society of Transplantation Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13499. DOI: 10.1111/ctr.13499.
    [26] MAMATIS JE, PELLIZZARI-DELANO IE, GALLARDO-FLORES CE, et al. Emerging roles of cyclophilin A in regulating viral cloaking[J]. Front Microbiol, 2022, 13: 828078. DOI: 10.3389/fmicb.2022.828078.
    [27] HAN J, LEE MK, JANG Y, et al. Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents[J]. Drug Discov Today, 2022, 27(7): 1895-1912. DOI: 10.1016/j.drudis.2022.05.016.
    [28] GATHOGO E, HARBER M, BHAGANI S, et al. Impact of tacrolimus compared with cyclosporin on the incidence of acute allograft rejection in human immunodeficiency virus-positive kidney transplant recipients[J]. Transplantation, 2016, 100(4): 871-878. DOI: 10.1097/TP.0000000000000879.
    [29] VAN MAARSEVEEN EM, ROGERS CC, TROFE-CLARK J, et al. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review[J]. AIDS Patient Care STDS, 2012, 26(10): 568-581. DOI: 10.1089/apc.2012.0169.
    [30] HHS. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents 2011[EB/OL]. [2024-01-07].https://health.gov/healthypeople/tools-action/browse-evidence-based-resources/guidelines-use-antiretroviral-agents-adults-and-adolescents-living-hiv.
    [31] CRATER JM, NIXON DF, FURLER O'BRIEN RL. HIV-1 replication and latency are balanced by mTOR-driven cell metabolism[J]. Front Cell Infect Microbiol, 2022, 12: 1068436. DOI: 10.3389/fcimb.2022.1068436.
    [32] VARCO-MERTH BD, BRANTLEY W, MARENCO A, et al. Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy[J]. J Clin Invest, 2022, 132(10): e156063. DOI: 10.1172/JCI156063.
    [33] PLANAS D, PAGLIUZZA A, PONTE R, et al. LILAC pilot study: effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy[J]. EBioMedicine, 2021, 65: 103270. DOI: 10.1016/j.ebiom.2021.103270.
    [34] HENRICH TJ, SCHREINER C, CAMERON C, et al. Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: a prospective study[J]. Am J Transplant, 2021, 21(5): 1765-1779. DOI: 10.1111/ajt.16244.
    [35] MALAT GE, RANGANNA KM, SIKALAS N, et al. High frequency of rejections in HIV-positive recipients of kidney transplantation: a single center prospective trial[J]. Transplantation, 2012, 94(10): 1020-1024. DOI: 10.1097/TP.0b013e31826c3947.
    [36] LOCKE JE, JAMES NT, MANNON RB, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients[J]. Transplantation, 2014, 97(4): 446-450. DOI: 10.1097/01.TP.0000436905.54640.8c.
    [37] WERBEL WA, BAE S, YU S, et al. Early steroid withdrawal in HIV-infected kidney transplant recipients: utilization and outcomes[J]. Am J Transplant, 2021, 21(2): 717-726. DOI: 10.1111/ajt.16195.
    [38] SANTEUSANIO A, BHANSALI A, DE BOCCARDO G, et al. Conversion to belatacept maintenance immunosuppression in HIV-positive kidney transplant recipients[J]. Clin Transplant, 2020, 34(10): e14041. DOI: 10.1111/ctr.14041.
    [39] EL SAKHAWI K, MELICA G, SCEMLA A, et al. Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients[J]. Clin Kidney J, 2020, 14(8): 1908-1914. DOI: 10.1093/ckj/sfaa231.
  • 加载中
计量
  • 文章访问数:  12
  • HTML全文浏览量:  4
  • PDF下载量:  1
  • 被引次数: 0
出版历程
  • 收稿日期:  2024-01-26
  • 网络出版日期:  2024-04-29

目录

    /

    返回文章
    返回